Cargando…
Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach
Emerging studies have demonstrated the potential of PI3Kδ blockade as an immunotherapy for solid tumours. In pre-clinical models, we recently demonstrated that anti-LAG3 immune checkpoint blockade vastly potentiated PI3Kδ-based immunotherapy, enabling successful tumour control in all treated mice.
Autores principales: | Lauder, Sarah N., Vanhaesebroeck, Bart, Gallimore, Awen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368216/ https://www.ncbi.nlm.nih.gov/pubmed/33824480 http://dx.doi.org/10.1038/s41416-021-01285-1 |
Ejemplares similares
-
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
por: Lauder, Sarah Nicol, et al.
Publicado: (2020) -
Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion
por: Lauder, Sarah N., et al.
Publicado: (2022) -
Antigen receptor signalling: a distinctive role for the p110δ isoform of PI3K
por: Okkenhaug, Klaus, et al.
Publicado: (2007) -
The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation
por: Guo, Hailong, et al.
Publicado: (2008) -
Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter
por: Whitehead, Maria A., et al.
Publicado: (2012)